Lilly, J&J, Pfizer and Sanofi back Teva fight against IRA drug negotiation program

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation program in the Inflation Reduction Act (IRA).

Two months ago, the company filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS) for how it was implementing the program. And now, several large companies are backing Teva’s effort.